Is olaparib cost-effective in metastatic castration-resistant prostate cancer patients with at least one favorable gene mutation in BRCA1, BRCA2 or ATM?

Pharmacogenomics, Ahead of Print.

Source: Future Medicine: Pharmacogenomics - September 14, 2021 Category: Genetics & Stem Cells Authors: Yiyuan Li Shen Lin Lixian Zhong Shaohong Luo Xiaoting Huang Xiaojia Huang Liangliang Dong Xiongwei Xu Xiuhua Weng Source Type: research